Based on the BeiGene Ltd stock forecast from 7 analysts, the average analyst target price for BeiGene Ltd is USD 257.81 over the next 12 months. BeiGene Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BeiGene Ltd is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, BeiGene Ltd’s stock price was USD 176.50. BeiGene Ltd’s stock price has changed by -1.59% over the past week, -7.35% over the past month and +0.22% over the last year.
No recent analyst target price found for BeiGene Ltd
No recent average analyst rating found for BeiGene Ltd
Company Overview BeiGene Ltd
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Read Less
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) ...Read More
Frequently Asked Questions About BeiGene Ltd (BGNE) Stock
Based on ratings from 7 analysts BeiGene Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on BGNE's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for BGNE is USD 257.81 over the next 12 months. The maximum analyst target price is USD 300 while the minimum anlayst target price is USD 152.5.
Unfortunately we do not have enough data on BGNE's stock to indicate if its overvalued.
The last closing price of BGNE's stock was USD 176.50.
The most recent market capitalization for BGNE is USD 20.24B.
Based on targets from 7 analysts, the average taret price for BGNE is projected at USD 257.81 over the next 12 months.
This means that BGNE's stock price may go up by +46.07% over the next 12 months.
We can't find any ETFs which contains BeiGene Ltd's stock.
As per our most recent records BeiGene Ltd has 10,600 Employees.
BeiGene Ltd's registered address is 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108.
You can get more information about it from BeiGene Ltd's website at https://www.beigene.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About BeiGene Ltd (BGNE) Stock
Based on ratings from 7 analysts BeiGene Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on BGNE's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for BGNE is USD 257.81 over the next 12 months. The maximum analyst target price is USD 300 while the minimum anlayst target price is USD 152.5.
Unfortunately we do not have enough data on BGNE's stock to indicate if its overvalued.
The last closing price of BGNE's stock was USD 176.50.
The most recent market capitalization for BGNE is USD 20.24B.
Based on targets from 7 analysts, the average taret price for BGNE is projected at USD 257.81 over the next 12 months.
This means that BGNE's stock price may go up by +46.07% over the next 12 months.
We can't find any ETFs which contains BeiGene Ltd's stock.
As per our most recent records BeiGene Ltd has 10,600 Employees.
BeiGene Ltd's registered address is 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108.
You can get more information about it from BeiGene Ltd's website at https://www.beigene.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BGNE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
